Panacea Biotec plans price cut of its pentavalent vaccine by 10-15%

06 Jun 2011 Evaluate

Panacea Biotec is planning to cut the prices of EasyFive, which among other things prevents tetanus and hepatitis B, by 10-15% in the coming years as it pledged its support to the GAVI alliance. At present, the drug is priced at $2.96 per dosage.

The new vaccine price reductions to some extent will help on donor support for GAVI and contribute to reducing GAVI’s funding challenge. The pentavalent vaccine combines five different vaccines in one injection to protect against five diseases diphtheria, pertussis, tetanus, hepatitis B and haemophilus influenzae.

The Global Alliance for Vaccines and Immunisation (GAVI) comprises governments of developing and donor countries, World Health Organization, UNICEF, the World Bank, vaccine makers, research and technical agencies, civil society, the Bill & Melinda Gates Foundation and other private philanthropists.

Panacea Biotec has a long term pact with UNICEF to supply 75 million doses of Easyfive for the year 2010, 2011 and 2012. The company introduced fully liquid pentavalent vaccine EasyFive in January 2005.

Panacea Biotec is one of India’s leading research based health management companies with established research, manufacturing and marketing capabilities.

Panacea Biotec Share Price

133.95 -1.75 (-1.29%)
14-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1545.25
Dr. Reddys Lab 5861.00
Cipla 1356.95
Zydus Lifesciences 984.75
Lupin 1635.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.